GP-100 antigen Completed Phase 2 Trials for Iris Melanoma / Extraocular Extension Melanoma / Stage IIIc Melanoma / Ciliary Body and Choroid Melanoma, Medium/Large Size / Stage IIIB Melanoma / Stage IV Melanoma / Stage IIIA Melanoma / Stage IIC Melanoma / Stage IIB Melanoma Treatment

Indications	Status	Purpose	Phase
DBCOND0030826 (Iris Melanoma) DBCOND0029487 (Extraocular Extension Melanoma) DBCOND0052015 (Stage IIIc Melanoma) DBCOND0030825 (Ciliary Body and Choroid Melanoma, Medium/Large Size) DBCOND0028890 (Stage IIIB Melanoma) DBCOND0028660 (Stage IV Melanoma) DBCOND0028889 (Stage IIIA Melanoma) DBCOND0028888 (Stage IIC Melanoma) DBCOND0028887 (Stage IIB Melanoma)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT00089063	Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma	GP-100 antigen (DB14800) Incomplete Freund's adjuvant (DB17475) Sargramostim (DB00020) Tyrosinase (DB16626)